Towards
Personalized Care
The Personalized Adjuvant Treatment for HR+/HER2- breast cancer for young patients (Path-for-young) project aims to establish and implement a new standard of care for young women with hormone receptor (HR) positive, human epidermal growth factor receptor (HER)2 negative breast cancer.
Perspective from a Patient in OPTIMA
Optima-young
A New Approach to Breast Cancer Treatment in Young Women
Path-for-young is based on a clinical trial recruiting premenopausal patients with HR+/HER2- breast cancer. This clinical trial, called Optima-young, aims to demonstrate that premenopausal patients with high-risk HR+HER2- breast cancer and receiving optimal endocrine therapy can be stratified to forego adjuvant chemotherapy without detriment to clinical outcome and resulting in improved long-term quality of life. Click on the video to learn more about the Optima-young clinical trial.
Participating countries
- in alphabetical order
Argentina, Australia, Belgium, Brazil, France, Greece, Ireland, Italy, Norway, New Zeland, Peru, Poland, Romania, Spain, UK
A Global Clinical Trial supporting the Path-for-young project to reduce chemotherapy for young women with breast cancer
Path-for-young is centered around a global, pragmatic randomized controlled trial that is focused on de-escalating chemotherapy among premenopausal patients with high-risk HR+HER2- breast cancer : the Optima-young clinical trial.
The project will leverage the existing ongoing Optima clinical trial and expand it by running an Optima-young clinical trial across a global multidisciplinary consortium, gathering leading international cooperative groups and associated sites from Europe, Latin America, and Oceania.
Participating countries
- in alphabetical order
Argentina, Australia, Belgium, Brazil, France, Greece, Ireland, Italy, Norway, New Zeland, Peru, Poland, Romania, Spain, UK
Patient co-creation
and representation
The Path-for-young project works to involve patients in a meaningful way throughout the project, from conception until dissemination of results. The main aims are understanding important aspects of the patient experience in a chemotherapy de-escalation trial, improving trial recruitment and implementation, ensuring that key patient needs are integrated into the trial development and conduct. The Path-for-young project has set up a working group that benefits from the expertise of several diverse clinical, academic, industrial and nonprofit partners to ensure that patients’ voices are taken into account in the project.
Partners
in alphabetical order
